Company intelligence / Profile preview

Previse

Halethorpe, Maryland, United Statesprevisedx.com ↗

Ownership: Private
Development stage: Commercial

Overview

Previse has launched Esopredict®, a molecular diagnostic test that uses proprietary epigenetic biomarkers to provide personalized guidance for the surveillance and treatment of patients with Barrett's esophagus. The company supports its product with ongoing clinical utility research. Clinical trial NCT05846971 evaluates how the assay influences gastroenterologists' management decisions in real-world settings. The company has raised over $10M in funding to date.

Therapeutic areas: GastroenterologyOncology
Modalities: Molecular diagnostic testEpigenetic biomarker assayDevice (for sample collection; inferred from industry context)
Industry: Molecular Diagnostics

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Previse.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Previse.

Explore the full profile